RemeGen Biosciences, Inc.
650 Gateway Blvd, Suite No. 110
South San Francisco
About RemeGen Biosciences, Inc.
RemeGen Biosciences, Inc. is committed to the discovery, development, and commercialization of innovative and differentiated biological drugs. We strive to continuously create value through our clinical studies to develop products that meet the unmet clinical needs. We aim to become a global leader in the pharmaceutical industry.
Company Ownership: Public
Stock Symbol: 9995.HK
Stock Exchange: HKSE
3 articles with RemeGen Biosciences, Inc.
RemeGen Reiterates Commitment to Its Battle Against Autoimmune Disease on World Strengthened Immunity Day 2021
YANTAI, China , Dec. 14, 2021 /PRNewswire/ -- To celebrate World Strengthened Immunity Day, RemeGen Co., Ltd. (9995.HK), a commercial-ready biotechnology company, reiterated its commitment to discovering, developing, and producing best-in-class biological drugs for autoimmune diseases, to create clinical value, and meet the major unmet clinical needs of the world. Since 19
RemeGen's Telitacicept and Disitamab Vedotin Enter China's National Reimbursement Drug List for SLE and Gastric Cancer Treatment
RemeGen Co., Ltd. announced that two of its innovative drugs, a dual-targeted TACI-Fc fusion protein, Telitacicept for treating systemic lupus erythematosus and a novel antibody-drug conjugate, Disitamab Vedotin for treating locally advanced or metastatic gastric cancer, have been officially included in this year's National Reimbursement Drug List.
Seagen and RemeGen Announce Exclusive Worldwide License and Co-Development Agreement for Disitamab Vedotin
Seagen Inc., a world leader and pioneer in antibody-drug conjugate therapies, and RemeGen Co., Ltd., a leading innovative biopharmaceutical company in China, announced that the two companies have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin, a novel HER2-targeted ADC.